Next Article in Journal
RNA Detection in Live Bacterial Cells Using Fluorescent Protein Complementation Triggered by Interaction of Two RNA Aptamers with Two RNA-Binding Peptides
Next Article in Special Issue
Functional Consequences of GPCR Heterodimerization: GPCRs as Allosteric Modulators
Previous Article in Journal
Myocardial Opioid Receptors in Conditioning and Cytoprotection
Open AccessOpinion

Neuropeptide Receptors: Novel Targets for HIV/AIDS Therapeutics

by Donald R. Branch 1,2,3
1
Department of Medicine, University of Toronto, Toronto, Ontario M5G 2M1, Canada
2
Department Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5G 2M1, Canada
3
Research & Development, Toronto Immunology Hub, Canadian Blood Services, Toronto, Ontario M5G 2M1, Canada
Pharmaceuticals 2011, 4(3), 485-493; https://doi.org/10.3390/ph4030485
Received: 3 February 2011 / Revised: 4 March 2011 / Accepted: 7 March 2011 / Published: 9 March 2011
(This article belongs to the Special Issue GPCR Based Drug Discovery)
The vasoactive intestinal peptide/pituitary adenylyl cyclase-activating polypepetide (VPAC) receptors are important for many physiologic functions, including glucose homeostasis, neuroprotection, memory, gut function, modulation of the immune system and circadian function. In addition, VPAC receptors have been shown to function in vitro to modulate the infection of HIV by a signal transduction pathway that appears to regulate viral integration. In this article, the affects of VPAC stimulation on HIV infection will be reviewed and approaches for the development of HIV/AIDS therapeutics that target these receptors will be described. Novel HIV/AIDS therapeutics are urgently required to stem the continued spread of this disease, particularly in underdeveloped countries. Drug design to inhibit signaling through VPAC1 and stimulate signaling through VPAC2 could lead to alternative therapies for the treatment and/or prevention of HIV/AIDS. View Full-Text
Keywords: neuropeptide receptors; HIV/AIDS; VPAC1; VPAC2; HIV therapeutics neuropeptide receptors; HIV/AIDS; VPAC1; VPAC2; HIV therapeutics
MDPI and ACS Style

Branch, D.R. Neuropeptide Receptors: Novel Targets for HIV/AIDS Therapeutics. Pharmaceuticals 2011, 4, 485-493.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop